Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

Impact · against what's priced in

Neuronetics has reached a critical financial inflection point by achieving positive operating cash flow and strong clinic revenue growth. While core device sales remain stagnant, the shift toward self-sufficiency and successful scaling of the Greenbrook acquisition provide a meaningful positive catalyst.

STIM+0.60

No priced-in read yet